Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (uv, Formaldehyde Inactivated)

For most adults (ages 18 through 64), the standard dosage of the Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen is administered as a single 0.5 mL intramuscular injection. This dose typically contains 15 micrograms (mcg) of the hemagglutinin (HA) antigen for this specific B strain, alongside 15 mcg each of the other three strains in a quadrivalent vaccine (total 60 mcg HA).

For adults aged 65 and older, a "High-Dose" version is often recommended. This formulation contains 60 mcg of the B/austria/1359417/2021 antigen (total 240 mcg HA across all four strains). Clinical trials have demonstrated that this higher concentration is necessary to elicit a robust protective antibody response in older adults whose immune systems may not respond as vigorously to standard doses.

The pediatric dosage depends on the child's age and previous vaccination history:

• Infants 6 months through 35 months: Depending on the specific vaccine brand, the dose may be 0.25 mL or 0.5 mL.
• Children 3 years through 8 years: Usually a 0.5 mL dose. If the child has not received at least two doses of influenza vaccine in their lifetime prior to July 1st of the current year, they require two doses administered at least 4 weeks apart. This 'prime-boost' strategy is essential to ensure the child develops adequate immunity.
• Children 9 years and older: A single 0.5 mL dose is sufficient, regardless of prior vaccination history.

Renal Impairment

No dosage adjustments are required for patients with renal (kidney) impairment. The antigen is not cleared by the kidneys, and clinical data suggest the safety profile remains unchanged in patients with chronic kidney disease or those on dialysis.

Hepatic Impairment

No dosage adjustments are necessary for patients with hepatic (liver) impairment. As the vaccine is processed by the immune system and not the cytochrome P450 enzyme system in the liver, liver dysfunction does not affect the vaccine's metabolism or safety.

Elderly Patients

As noted above, elderly patients (65+) are generally encouraged to receive the high-dose or adjuvanted formulations to ensure adequate protection. However, the standard dose is still safe if the high-dose version is unavailable.

This medication is administered exclusively by a healthcare professional. It is given as an intramuscular (IM) injection. The preferred site for adults and older children is the deltoid muscle of the upper arm. In infants and small children, the anterolateral aspect of the thigh is the preferred site due to larger muscle mass.

• Preparation: The vaccine should be shaken well before administration to ensure a uniform suspension. It should be inspected visually for particulate matter or discoloration.
• Timing: Vaccination should ideally occur before the onset of influenza activity in the community, typically by the end of October in the Northern Hemisphere.
• Storage: The vaccine must be stored under refrigeration (2°C to 8°C or 36°F to 46°F). It must never be frozen; if freezing occurs, the antigen structure may be compromised, and the vaccine must be discarded.

If a child requires two doses and misses the second one, it should be administered as soon as possible. There is no need to restart the series if the gap is longer than 4 weeks, but the child is not fully protected until the second dose is received. For adults, if the annual window is missed, vaccination can still be beneficial as long as influenza viruses are circulating (even as late as May).

An overdose of a vaccine antigen is extremely rare and typically involves receiving a second injection too soon. While not life-threatening, it may increase the severity of local injection site reactions (pain, swelling) or systemic symptoms (fever). There is no specific treatment for a vaccine overdose other than supportive care (e.g., acetaminophen for fever).

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most individuals who receive the Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen will experience mild, transient side effects. These are actually signs that the immune system is responding to the antigen. Common reactions include:

• Injection Site Pain: Occurs in over 60% of recipients. It typically feels like a dull ache in the deltoid muscle and usually resolves within 24 to 48 hours.
• Fatigue: A general feeling of tiredness or lethargy as the body diverts energy to the immune response.
• Headache: Mild to moderate tension-type headache.
• Myalgia (Muscle Aches): Generalized body aches, similar to the early stages of a cold, but without the respiratory symptoms.
• Erythema (Redness): A small red patch at the site of the needle entry.

• Fever: Usually low-grade (below 101°F or 38.3°C). Higher fevers are more common in children than in adults.
• Nausea: Mild stomach upset or loss of appetite, particularly in pediatric populations.
• Induration (Hardness): A firm lump at the injection site that may last for several days.
• Chills: Feeling cold or shivering briefly after the injection.

• Lymphadenopathy: Swelling of the lymph nodes in the armpit (axilla) on the side where the shot was given.
• Syncope (Fainting): This is usually a vasovagal response to the needle itself rather than the antigen. It is most common in adolescents.
• Urticaria (Hives): A mild allergic skin reaction.

> Warning: Stop taking Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (uv, Formaldehyde Inactivated) and call your doctor immediately if you experience any of these.

• Anaphylaxis: A severe, life-threatening allergic reaction. Symptoms include difficulty breathing, swelling of the throat or tongue, rapid heartbeat, and a sharp drop in blood pressure. This typically occurs within minutes of administration.
• Guillain-Barré Syndrome (GBS): A rare neurological disorder where the body’s immune system attacks the nerves. Symptoms include weakness or a tingling sensation in the legs that can spread to the upper body, potentially leading to paralysis. The risk is estimated at 1 to 2 additional cases per million people vaccinated.
• Shoulder Injury Related to Vaccine Administration (SIRVA): Severe pain and limited range of motion in the shoulder caused by the needle being injected too high or too deep into the joint space rather than the muscle.
• Bell’s Palsy: Sudden weakness or paralysis of facial muscles, though a definitive causal link to the B/austria antigen is not firmly established.

There are no known long-term side effects associated with the B/austria/1359417/2021 Bvr-26 antigen. The viral proteins are cleared from the body within days, and the only long-term presence is the 'memory' of the immune system in the form of antibodies and T-cells. Large-scale safety monitoring by the CDC (VAERS) has not identified any chronic health conditions linked to seasonal flu antigens.

No FDA black box warnings have been issued for Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen. It is considered one of the safest pharmacological interventions available. However, the FDA requires that all facilities administering the vaccine have emergency equipment (such as epinephrine) available to treat potential anaphylaxis.

Report any unusual symptoms to your healthcare provider.

Before receiving the Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen, it is vital to disclose your full medical history to your healthcare provider. While generally safe, certain underlying conditions may require a delay in vaccination or a specific type of formulation. This antigen is inactivated, meaning it cannot cause the flu; however, it does not protect against other respiratory viruses like the common cold or COVID-19.

No FDA black box warnings for Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (uv, Formaldehyde Inactivated).

• Allergic Reactions / Anaphylaxis Risk: If you have a known severe allergy to any component of the vaccine (such as formaldehyde, used in the inactivation process, or neomycin/polymyxin, used to prevent bacterial growth during manufacturing), you should not receive this specific product.
• Egg Allergy: Most versions of this antigen are grown in eggs. While the CDC now states that most people with egg allergies can safely receive any flu vaccine, those with a history of severe anaphylaxis to eggs should be vaccinated in a medical setting supervised by a physician.
• Guillain-Barré Syndrome (GBS): If you have ever had GBS within 6 weeks of a previous influenza vaccination, your doctor will carefully weigh the risks and benefits of giving you the B/austria/1359417/2021 antigen.
• Acute Febrile Illness: If you have a moderate to severe illness with a fever, vaccination should typically be postponed until you have recovered. A mild cold without a fever is generally not a reason to delay the shot.
• Immunocompromised Patients: People with weakened immune systems (due to HIV, cancer, or immunosuppressive drugs) may have a reduced immune response to the antigen. They are still encouraged to get vaccinated, as they are at high risk for flu complications, but they should be aware that protection may not be 100%.

There are no routine lab tests (like blood counts or liver panels) required before or after receiving this antigen. However, patients who are on anticoagulants (blood thinners) should be monitored for hematoma (bruising/bleeding) at the injection site, as the intramuscular route can cause localized bleeding in these individuals.

The B/austria/1359417/2021 antigen has no known effect on the ability to drive or operate heavy machinery. However, if you experience rare side effects like dizziness or fainting (syncope) immediately after the shot, you should wait until these symptoms resolve before driving.

There is no direct interaction between alcohol and the Influenza B antigen. However, heavy alcohol consumption can suppress the immune system, potentially reducing the effectiveness of the vaccine. It is advisable to avoid excessive drinking for a few days following vaccination to allow the immune system to focus on building antibodies.

As this is a single-dose (or two-dose for children) immunization, 'discontinuation' is not applicable. There is no withdrawal syndrome. However, failing to receive the annual update means you will not be protected against the specific strains predicted for the following year.

> Important: Discuss all your medical conditions with your healthcare provider before starting Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (uv, Formaldehyde Inactivated).

There are no absolute drug-drug contraindications that would result in a fatal interaction. However, the use of immunosuppressive therapies (such as high-dose corticosteroids, alkylating agents, or antimetabolites) may significantly diminish the immune response to the Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen. In these cases, the vaccine is not dangerous, but it may be ineffective.

• Anticoagulants (Warfarin, Heparin, Apixaban): While not an interaction with the antigen itself, the physical act of intramuscular injection can cause significant bleeding or hematoma in patients on these medications. A fine-gauge needle should be used, and firm pressure should be applied to the site for at least 2 minutes.
• Chemotherapy: Vaccination should ideally be timed between chemotherapy cycles when the white blood cell count is at its highest to ensure the best possible immune response.

• Statin Medications: Some studies have suggested that statins (cholesterol-lowering drugs) might slightly reduce the antibody response to influenza vaccines. However, the clinical significance is debated, and patients are strongly advised to continue their statins and still receive the flu vaccine.
• Acetaminophen/NSAIDs: While taking these after the shot to treat a fever is fine, some evidence suggests that taking them prophylactically (before the shot) might slightly dampen the initial immune activation. It is best to wait until symptoms appear before taking pain relievers.

There are no known food interactions with the B/austria/1359417/2021 antigen. You may eat and drink normally before and after the injection. Unlike some oral medications, dairy, grapefruit juice, and caffeine do not affect the intramuscular processing of viral antigens.

• Echinacea and Elderberry: These are often taken to 'boost' the immune system. While there is no evidence of harm when combined with the flu vaccine, there is also no clinical evidence that they improve the vaccine's efficacy.
• Immunosuppressive Herbs: High doses of certain herbs that may have mild immunosuppressive properties (like Tripterygium wilfordii) should be discussed with a doctor, as they might theoretically reduce the vaccine's effectiveness.

• False Positive HIV/HCV Tests: There have been rare reports of transient false-positive results on certain enzyme-linked immunosorbent assays (ELISA) for HIV-1, Hepatitis C, and HTLV-1 following influenza vaccination. This is due to cross-reactive IgM antibodies produced in response to the vaccine. If a positive result occurs shortly after vaccination, a more specific confirmatory test (like a Western Blot or PCR) should be performed.

For each major interaction, explain:

• The mechanism: Most interactions are pharmacodynamic (affecting the body's response) rather than pharmacokinetic (affecting drug levels).
• The clinical consequence: Reduced protection against the flu.
• Management strategy: Timing the vaccine during periods of relative immunocompetence.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

There are very few absolute contraindications for the Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen, as it is an inactivated product. However, it must NEVER be used in the following circumstances:

• Severe Allergic Reaction (Anaphylaxis): If a patient has had a life-threatening allergic reaction to a previous dose of any influenza vaccine or to any specific component of this vaccine (e.g., formaldehyde, egg protein, or antibiotics used in production). The mechanism is an IgE-mediated hypersensitivity that could lead to airway obstruction and circulatory collapse upon re-exposure.
• Infants under 6 months of age: The safety and efficacy of this antigen have not been established in infants younger than 6 months. Furthermore, infants in this age group typically do not mount an effective immune response to the vaccine and are protected instead by maternal antibodies (if the mother was vaccinated during pregnancy).

These are conditions where the healthcare provider will perform a risk-benefit analysis:

• History of Guillain-Barré Syndrome (GBS): If GBS occurred within 6 weeks of a prior influenza vaccine, the risk of a recurrence is theoretically present, though very low. In most cases, the risk of severe flu complications outweighs the risk of recurrent GBS, but the decision must be individualized.
• Moderate or Severe Acute Illness: To avoid diagnostic confusion between the symptoms of the illness and the side effects of the vaccine, vaccination should be delayed until the patient is stable.

Patients with known sensitivities to other Influenza B strains (such as B/Phuket or B/Washington) are likely to be sensitive to the B/austria strain as well, as the manufacturing processes and viral structures are highly similar. Additionally, those with sensitivities to aminoglycoside antibiotics (like neomycin) should check the specific vaccine brand's package insert, as trace amounts may be present from the manufacturing process.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen (uv, Formaldehyde Inactivated).

Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen is strongly recommended for pregnant individuals.

• FDA Pregnancy Category: Traditionally classified as Category B or C (depending on the specific brand).
• Risks: There is no evidence of teratogenicity (birth defects) associated with inactivated flu antigens.
• Benefits: Pregnant women are at significantly higher risk for severe complications, hospitalization, and death from Influenza B. Vaccination also provides "passive immunity" to the newborn, protecting the baby for the first several months of life when they are too young to be vaccinated themselves. Vaccination is safe in any trimester.

It is safe to receive the B/austria/1359417/2021 antigen while breastfeeding. The inactivated viral particles do not pass into breast milk, but the beneficial antibodies (IgA) produced by the mother do. This helps protect the nursing infant from influenza infection. There is no evidence of adverse effects on milk production or the health of the nursing infant.

As mentioned, this antigen is approved for children 6 months and older.

• Growth Effects: There are no known effects on growth or development.
• Special Considerations: Children aged 6 months to 8 years require two doses if it is their first time being vaccinated. This is because their immune systems are "immunologically naive" to the B/Victoria lineage and require a second exposure to develop protective levels of antibodies.

Adults 65 years and older are at the highest risk for flu-related mortality.

• Pharmacokinetic Changes: While the distribution of the antigen doesn't change, the response does. Immunosenescence leads to lower antibody titers.
• High-Dose Recommendation: Clinical guidelines frequently recommend the High-Dose Quadrivalent vaccine for this population, which contains a higher concentration of the B/austria/1359417/2021 antigen to ensure protection.

Patients with end-stage renal disease (ESRD) or those on hemodialysis can safely receive the antigen. They are considered a high-priority group for vaccination due to their increased risk of infection. No dose adjustment is needed, although their antibody response may be slightly lower than that of the general population.

There are no specific concerns for patients with cirrhosis or other forms of liver disease. The vaccine is safe and recommended, as influenza can trigger hepatic decompensation in patients with fragile liver function.

> Important: Special populations require individualized medical assessment.

The Influenza B Virus B/austria/1359417/2021 Bvr-26 Antigen acts as an exogenous (external) immunogen. The primary target is the Hemagglutinin (HA) protein on the viral surface. The HA protein normally binds to sialic acid receptors on human respiratory epithelial cells. By introducing inactivated HA into the body, the vaccine induces the production of neutralizing antibodies. These antibodies bind to the 'globular head' of the HA protein, physically blocking the virus from attaching to and entering host cells. This prevents viral replication and the subsequent clinical syndrome of influenza.

The dose-response relationship of this antigen is measured by "seroconversion" and "seroprotection" rates.

• Onset: Antibodies begin to appear within 7 days, but protective levels (usually defined as a Hemagglutination Inhibition [HI] titer of 1:40 or greater) are typically reached 14 to 21 days post-injection.
• Duration: Protection generally lasts for the duration of one flu season (approx. 6 months).
• Tolerance: There is no development of pharmacological tolerance; however, the virus itself undergoes "antigenic drift," which is why the antigen must be updated annually.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Intramuscular Injection) |

| Protein Binding | N/A |

| Half-life | Antigen cleared within 48-72 hours; Antibodies last ~6-12 months |

| Tmax | 2-4 weeks (for peak antibody titers) |

| Metabolism | Cellular proteolysis in macrophages |

| Excretion | Cellular debris cleared via lymphatic/reticuloendothelial system |

The antigen consists of purified viral subunits. The B/austria/1359417/2021 strain is a B/Victoria-like virus. The inactivation process involves treatment with Formaldehyde, which creates methylene cross-links between protein amino groups, and UV light, which causes thymine dimers in the viral RNA, rendering it incapable of replication. The final product is a sterile aqueous suspension.

This antigen is classified as an Inactivated Viral Vaccine. It is part of the broader category of Biologicals and Immunomodulators. Within the seasonal influenza vaccine, it is specifically the B-component, distinguished from the A-components (H1N1 and H3N2) by its genetic lineage and host range (Influenza B almost exclusively infects humans).